低甲基化驱动的 AKT 丝氨酸/苏氨酸激酶 3 促进睾丸生殖细胞肿瘤增殖并与免疫浸润负相关

AKT Serine/Threonine Kinase 3 (AKT3) has been reported to play an important role in different tumors.

However, its clinical value, biological function, and molecular mechanism in testicular germ cell tumors (TGCT) remains unclear. In the current study, we applied the Gene Set Cancer Analysis (GSCA), UCSC XENA, Gene Expression Omnibus (GEO), the Human Protein Atlas (HPA), LinkedOmics, DiseaseMeth version 2. 0, TISIDB, and other databases for TGCT data mining. Then, we investigated AKT3's mechanism of action and clinical survival significance via bioinformatics followed by in vitro experiments.

We found that AKT3 was upregulated and had frequent copy number amplifications in TGCT, which were associated with poor survival outcomes of patients. On the other hand, mutations that led to AKT3 loss-of-function were correlated to a better prognosis in patients.

Moreover, AKT3 silencing significantly inhibited the proliferation, DNA synthesis and colony formation of NCCIT cells (a TGCT cell line). AKT3 might participate in TGCT progression through multiple signaling pathways, such as ErbB, oxidative phosphorylation, and affecting tumor immune infiltration. Also, the upregulation of AKT3 mRNA expression might be driven by the hypomethylation of its promoter region.

Overall, AKT3 is a potential TGCT oncogene and can be further used as a therapeutic target.